Wipfli Financial Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Wipfli Financial Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$41K	Buy	+630	New	+$45.7K	﹤0.01%	1193

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wipfli Financial Advisors's CRSP Position: Q3 2022 in Review

Wipfli Financial Advisors opened a new position in CRISPR Therapeutics (CRSP) in Q3 2022: 630 shares worth $41K. The stake represents ﹤0.01% of the portfolio and ranks #1193 among its holdings.

436 funds tracked by Wall St. Rank hold CRSP as of Q3 2022.

Wipfli Financial Advisors held 630 shares of CRISPR Therapeutics worth $41K as of Q3 2022.
CRISPR Therapeutics was a new Wipfli Financial Advisors position in Q3 2022.
CRISPR Therapeutics made up ﹤0.01% of Wipfli Financial Advisors's portfolio in Q3 2022, its #1193 holding.
436 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2022.

Based on Wipfli Financial Advisors's 13F filing for Q3 2022, filed 26 Oct 2022.